Testing Curcumin with Palliative Radiation Therapy in Women with Advanced Cervical Cancer

What this Trial Is About

Researchers are evaluating the addition of curcumin as an extra treatment for women with advanced cervical cancer receiving standard palliative radiotherapy. This open-label pilot trial aims to test whether combining curcumin with radiation is feasible, safe, and whether it improves treatment response. The study also examines how much curcumin is absorbed and how long it stays in the body, focusing on patients with FIGO stage IIIB to IVA cervical cancer. Participants will take 250 mg capsules of a specially formulated curcumin with enhanced bioavailability four times a day for 4 to 6 weeks, starting seven days before and continuing during the course of palliative radiotherapy. The radiotherapy treatment follows local guidelines, delivering a biologically effective dose of 45-55 Gy over three to five weeks. This combined treatment approach is being carefully monitored during the study period. During the trial, participants will provide blood and urine samples for lab tests and curcumin level measurements. They will undergo CT scans to assess tumor response and complete questionnaires to evaluate changes in quality of life. Researchers will measure treatment fidelity, objective response rate, disease control, adverse events, dose adjustments, and quality-of-life improvements over 13 to 17 weeks. The study includes safety monitoring and follow-up assessments lasting up to 14 weeks, with data collection continuing for about one year.

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial